Gemtuzumab Ozogamicin

證據等級: L5

預測適應症: 10 個

Gemtuzumab Ozogamicin: From Acute Myeloid Leukemia to Chronic Myeloid Leukemia, Blast Phase (BCR-ABL1 Positive)

One-Sentence Summary

Gemtuzumab ozogamicin (Mylotarg) is a CD33-targeted antibody-drug conjugate originally used for CD33-positive acute myeloid leukemia (AML). Among the 10 indications TxGNN predicted for this drug, Chronic Myeloid Leukemia, Blast Phase (BCR-ABL1 Positive) is the only candidate with a plausible biological mechanism and meaningful supporting evidence — 3 clinical trials and 13 publications — while the model’s top-scoring predictions (e.g. Richter syndrome, bulbar polio, malignant spiradenoma) were assessed in the evidence pack itself as likely model noise with no mechanistic basis or supporting data.

Quick Overview

Item	Content
Original Indication	CD33-positive Acute Myeloid Leukemia (AML) — derived from literature within the evidence pack; no structured original-indication record was available
Predicted New Indication	Chronic Myeloid Leukemia, Blast Phase (BCR-ABL1 Positive)
TxGNN Prediction Score	97.89%
Evidence Level	L3
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Note on candidate selection: This evidence pack scored gemtuzumab ozogamicin against 10 predicted indications. Six of them (Richter syndrome, bulbar polio, malignant spiradenoma, 5q35 microduplication syndrome, neuralgic amyotrophy, and its duplicate “amyotrophic neuralgia”) received the highest TxGNN scores but have zero supporting trials or literature, and the evidence pack’s own mechanistic review flags them as implausible or as likely ontology/false-positive noise (all scored L5, Hold). CML blast phase, ranked third by score, is the only candidate with a coherent CD33-related mechanism and a real evidence base, and is therefore the focus of this report.

Why is This Prediction Reasonable?

Detailed structured mechanism-of-action data for gemtuzumab ozogamicin was not available in this evidence pack (flagged as a High-severity data gap). However, the literature retrieved within the pack itself is consistent and specific: gemtuzumab ozogamicin is a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic agent calicheamicin, designed to deliver a cytotoxic payload to CD33-expressing myeloid blasts (PMID 15454492, 15886328).

The drug’s approved use is in CD33-positive AML. Chronic myeloid leukemia in blast phase (CML-BP) is pathologically similar to AML at that stage — blast-phase disease is managed largely like AML because of shared histological and clinical features (PMID 35536916). Critically, CD34+/CD38- leukemic stem cells in CML have been shown to express CD33 (Siglec-3) and to respond to gemtuzumab ozogamicin in vitro (PMID 21993666), giving a direct molecular rationale for activity in this setting.

This mechanistic plausibility is reinforced by real-world clinical use: gemtuzumab ozogamicin has been combined with fludarabine/cytarabine in CML-BP patients (PMID 22534616) and used together with blinatumomab in refractory mixed-phenotype CML blast crisis (PMID 34764108), indicating clinicians have already explored this off-label use in difficult, CD33-expressing blast-phase disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00038831	Phase 1/2	Completed	47	Mylotarg combined with melphalan/fludarabine as reduced-intensity conditioning before allogeneic transplant in high-risk acute leukemia, CML, or MDS
NCT03589729	Phase 2	Recruiting	100	Dexrazoxane cardioprotection during chemotherapy regimens (including gemtuzumab ozogamicin) in AML, high-risk MDS, myeloid blast phase CML, and Ph+ AML
NCT00038805	Phase 2/3	Terminated (n=3)	3	Nonmyeloablative allogeneic transplant using Mylotarg-based conditioning in high-risk ALL, CML, or MDS

None of these trials is a dedicated randomised efficacy trial of gemtuzumab ozogamicin specifically for CML blast phase — all are transplant-conditioning or supportive-care studies that include CML-BP as one of several eligible diagnoses.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35536916	2022	Systematic Review	Expert Review of Hematology	CML myeloid blast phase resembles AML clinically and histologically; management is drawn from AML strategies
22534616	2012	Cohort (n=107)	Clin Lymphoma Myeloma Leuk	Fludarabine + cytarabine ± gemtuzumab ozogamicin in relapsed/refractory AML, high-risk MDS, and CML blast phase; 26% complete remission rate overall
34764108	2021	Case Report	BMJ Case Reports	Gemtuzumab ozogamicin plus blinatumomab used in refractory mixed-phenotype CML blast crisis
21993666	2012	Mechanistic Study	Haematologica	CD34+/CD38- leukemic stem cells in CML express CD33 (Siglec-3) and respond to gemtuzumab ozogamicin in vitro
17353625	2007	Review	Gan to Kagaku Ryoho	Overview of hematological malignancy therapy including CD33-targeted gemtuzumab ozogamicin in AML
15454492	2005	Mechanistic Study	Blood	CD33 expression level and internalization kinetics determine gemtuzumab ozogamicin cytotoxicity
15487459	2004	Review	American Journal of Clinical Pathology	Overview of targeted cancer therapies including gemtuzumab ozogamicin and BCR-ABL–targeted imatinib in CML
15886328	2005	Clinical Trial	Blood	Dose-escalation safety/efficacy study of gemtuzumab ozogamicin in pediatric CD33+ AML
11895761	2002	Case Series (n=23)	Blood	Hepatic sinusoidal obstruction (veno-occlusive disease) following gemtuzumab ozogamicin in transplant patients
11466696	2001	Case Series	Cancer	Hepatic veno-occlusive disease associated with gemtuzumab ozogamicin even without prior stem cell transplant

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — antibody-drug conjugate (anti-CD33 monoclonal antibody linked to the cytotoxic agent calicheamicin)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions — no myelosuppression-specific toxicity data available in this evidence pack
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Liver function tests are a priority — hepatic sinusoidal obstruction syndrome/veno-occlusive disease is a recurring toxicity signal in the literature (PMID 11466696, 11895761); full blood count given the CD33+ myeloid cell target
Handling Protection	Cytotoxic drug handling precautions apply (antibody-drug conjugate with a cytotoxic payload)

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No structured warnings, contraindications, or drug-interaction data were available in this evidence pack, and this is flagged as a Blocking data gap preventing formal safety pre-assessment.

Conclusion and Next Steps

Decision: Hold

Rationale:

Mechanistic plausibility and some real-world clinical use exist for gemtuzumab ozogamicin in CML blast phase (CD33 expression on CML leukemic stem cells, combination use in refractory blast crisis), but no trial has directly tested efficacy for this indication — all identified trials are transplant-conditioning or supportive-care studies, and no completed Phase 2/3 RCT exists.
A TGA-equivalent Product Information gap (warnings/contraindications) is a Blocking issue that prevents even an initial safety assessment, and the drug is not currently marketed in Australia (0 ARTG entries).

To proceed, the following is needed:

TGA-approved Product Information (warnings, contraindications, drug interactions)
Structured mechanism-of-action data from DrugBank to confirm the CD33/calicheamicin pathway formally
A dedicated efficacy study (ideally prospective) in CML blast-phase patients rather than reliance on mixed-diagnosis transplant/conditioning trials
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.